WebJul 1, 2003 · Barbara Scheiber-Mojdehkar Intravenous iron, used for the treatment of anemia in chronic renal failure and other diseases, represents a possible source of free iron in tissue cells, particularly ... WebBarbara Fentum, Sanjoy K. Paul, Susan J. Carr, Thompson G. Robinson; Published in issue: March 2005. p1019-1027. Full-Text HTML; PDF Down-regulation of hepatic LDL …
Novel p53-dependent anticancer strategy by targeting iron
WebKHATAMI M, HEIDARI MM, HADADZADEH M, SCHEIBER-MOJDEHKAR B, BITARAF SANI M, HOUSHMAND M. Simultaneous Genotyping of the Rs4762 and Rs699 Polymorphisms in Angiotensinogen Gene and Correlation with Iranian CAD Patients with Novel Hexa-primer ARMS-PCR. Iran J Public Health. 2024;46(6):811-819. Web10 Scheiber-Mojdehkar B, Sturm B, Plank L, Kryzer I, Goldenberg H. Influence of parenteral iron preparations on non-transferrin bound iron uptake, the iron regulatory … ish shell aria2
Bioavailability and stability of intravenous iron sucrose originator ...
WebFCM has low bioavailability for liver parenchyma cells, therefore liver iron deposition is unlikely and effects on hepcidin expression should be investigated in clinical studies. Intravenous iron preparations, like iron sucrose (IS) and ferric carboxymaltose (FCM) differ in their physicochemical stability. Thus differences in storage and utilization can be … WebEppie M Yiu, Geneieve Tai, Roger E Peverill, Katherine J Lee, Kevin D Croft, Trevor A Mori, Barbara Scheiber-Mojdehkar, Brigitte Sturm, Monika Praschberger, Adam P Vogel, … WebThe team of Barbara Scheiber-Mojdehkar and Brigitte Sturm focus on two main aspects of iron regulation: Iron deficiency occurs often in patients undergoing regular dialysis. … safari club international 2023